all-trans retinoic acid

Overview

All-trans retinoic acid (ATRA) is the biologically active, fully conjugated isomer of retinoic acid, itself a metabolite of vitamin A (retinol). As a small-molecule ligand for nuclear retinoic acid receptors (RARs) — particularly retinoic acid receptor alpha (RARα) — ATRA functions as a transcriptional regulator that governs a broad range of cellular programs including differentiation, proliferation, apoptosis, and immune modulation. Upon binding RARα, ATRA-receptor complexes translocate to retinoic acid response elements (RAREs) in gene promoters, directly activating or repressing target gene transcription. This mechanism underpins ATRA's most celebrated clinical application: the induction of terminal differentiation in acute promyelocytic leukemia (APL) blast cells, where it remains a cornerstone of curative therapy. Beyond oncology, ATRA exerts pleiotropic effects on immune cell phenotype, stromal architecture, and metabolic state, positioning it as a versatile pharmacological tool across a wide range of disease contexts.

ATRA's therapeutic relevance extends well beyond APL. It has been investigated in autoimmune hematological disorders, solid tumor microenvironment reprogramming, and combination immunotherapy regimens. Its capacity to simultaneously modulate antigen-presenting cells, reshape the extracellular matrix, and influence metabolic signaling pathways — including hypoxia-inducible factor-1α (HIF-1α) and AMPK/mTOR axes — makes ATRA a compound of sustained and expanding scientific interest.

Focus of Latest Publications

Recent publications have continued to examine all-trans retinoic acid (ATRA) as a biologically active modulator of immune and differentiation pathways across inflammatory and malignant settings. In chemotherapy-induced peripheral neuropathy, ATRA was studied ex vivo for its ability to modulate monocyte/macrophage phenotypes, consistent with its reported antioxidant and immunomodulatory properties and the role of persistent inflammation and oxidative stress in neuronal injury. In immune thrombocytopenia, ATRA was reported to improve megakaryopoiesis by correcting impaired proplatelet formation, with mechanistic data implicating up-regulation of the hypoxia-inducible factor-1α/SPHK2/S1P pathway and restoration of cytoskeletal organization.

Several recent studies focused on ATRA in hematologic malignancy and differentiation resistance. In non-APL acute myeloid leukemia, ATRA was compared with the RARA-selective agonist Am80 (tamibarotene), with both agents inducing highly similar molecular responses and myeloid differentiation, particularly when combined with LSD1/GCN5 inhibition and in the context of increased RARA expression. Another study investigated mechanisms underlying ATRA resistance in non-APL AML and solid tumors, reporting that mTOR inhibition can promote ATRA-induced cancer cell differentiation by overcoming a metabolic hyperactive state. Together, these studies reinforce the view that ATRA-driven differentiation is context dependent and may be enhanced by targeting cooperating metabolic or epigenetic pathways.

ATRA was also implicated in tumor-immune interactions and stromal remodeling. In a ferroptosis-based immunotherapy study, ATRA released from ferroptotic tumor cells was shown to directly target CD38 through RARα and activate TFEB, thereby promoting autophagy-dependent MHC-II expression in macrophages and enhancing antigen presentation; this was linked to improved anti-tumor immunity and synergy with anti-PD-1 therapy in preclinical models. In pancreatic ductal adenocarcinoma, ATRA was incorporated into a nanotheranostic platform together with SN-38 and Bi2O3 to reprogram the tumor microenvironment, mitigate radiation-induced fibrosis, reduce stromal barriers, and improve radio-chemotherapy efficacy and immune infiltration.